CYTK (Cytokinetics) Net Income From Continuing Operations : $-615.26 Mil (TTM As of Mar. 2025)

View and export this data going back to 2004. Start your Free Trial

What is Cytokinetics Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Cytokinetics's net income from continuing operations for the three months ended in Mar. 2025 was $-161.38 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2025 was $-615.26 Mil.

Cytokinetics Net Income From Continuing Operations Historical Data

The historical data trend for Cytokinetics's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytokinetics Net Income From Continuing Operations Chart

Cytokinetics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Income From Continuing Operations

Get a 7-Day Free Trial

-127.29

-215.31

-388.96

-526.24

-589.53

Cytokinetics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Net Income From Continuing Operations	Get a 7-Day Free Trial															-135.64	-143.32	-160.55	-150.02	-161.38

Cytokinetics Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-615.26 Mil.

Cytokinetics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytokinetics Inc (NAS:CYTK) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

KK3A:Germany KK3A:Germany

Address

350 Oyster Point Boulevard, South San Francisco, CA, USA, 94080

Website

https://www.cytokinetics.com

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Executives

Fady Ibraham Malik	officer: SVP Research & Early Dev	280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Robert I Blum	officer: EVP, Corp. Development & CBO	280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Muna Bhanji	director	C/O CYTOKINETICS, INCORPORATED, 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Andrew Callos	officer: EVP, Chief Commercial Officers	C/O CYTOKINETICS, INCORPORATED, 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Wendall Wierenga	director	12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
John T Henderson	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Robert Arthur Harrington	director	C/O CYTOKINETICS, INCORPORATED, 350 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080
B Lynne Parshall	director	2855 GAZELLE COURT, CARLSBAD CA 92010
Robert Wong	officer: VP, Chief Accounting Officer	280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Ching Jaw	officer: SVP Finance & CFO	280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Sandford D Smith	director	C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Santo J Costa	director
Kaye Edward M. Md	director	3450 MONTE VILLA PARKWAY, BOTHELL WA 98011
Mark A Schlossberg	officer: SVP - Legal & General Counsel	C/O IMPAX LABORATORIES, INC., 30831 HUNTWOOD AVENUE, HAYWARD CA 94544
David Cragg	officer: V.P., Human Resources	280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080